News Amgen Inc. Buenos Aires S.E.

Equities

AMGN

ARDEUT110665

End-of-day quote Buenos Aires S.E. Other stock markets 03:30:00 24/06/2024 am IST			5-day change	1st Jan Change
13,942 ^ARS	+4.20%		+10.93%	+49.37%

21/06	US FDA approves Roche's drug for a chronic blood disorder	RE
14/06	Amgen Gets FDA Approval to Treat Aggressive Leukemia Type with Blincyto	DJ

Summary

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

US FDA approves Roche's drug for a chronic blood disorder	22/06	RE
Amgen : Bringing Cardiovascular Care to the Heart of Communities	21/06	PU
Amgen : Continues to Propel BiTE® Technology Innovation	20/06	PU
Amgen Gets FDA Approval to Treat Aggressive Leukemia Type with Blincyto	15/06	DJ
Amgen : Continues to Propel BiTE® Technology Innovation	15/06	PU
Amgen Says FDA Approves Blincyto to Treat Type of Blood Cancer	15/06	MT
FDA APPROVES BLINCYTO® (BLINATUMOMAB) IN CD19-POSITIVE PHILADELPHIA CHROMOSOME-NEGATIVE B-CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA (B-ALL) IN THE CONSOLIDATION PHASE	15/06	PR
Amgen Inc. Announces U.S. Food and Drug Administration Approves Blincyto	15/06	CI
Sector Update: Health Care Stocks Softer Friday Afternoon	14/06	MT
RBC Raises Price Target on Amgen to $332 From $328, Maintains Outperform Rating	14/06	MT
RBC Raises Price Target on Amgen to $332 From $328, Maintains Outperform Rating	14/06	MT
Race Oncology Validates Efficacy of Blood Cancer Therapy in Animal Study; Shares Rise 6%	13/06	MT
AMGEN TO PRESENT INNOVATIVE RHEUMATOLOGY RESEARCH AT EULAR 2024	12/06	PR
Amgen : Leaders Hail Southern California’s Emergence as Biotech Innovation Hub	11/06	PU
Updates On Aflibercept Biosimilar Approvals And BPCIA Litigation	11/06	AQ
FDA Approves Amgen's BKEMV, The First Eculizumab Biosimilar	11/06	AQ
Transcript : Amgen Inc. Presents at Goldman Sachs 45th Annual Global Healthcare Conference, Jun-10-2024 09:20 AM	10/06
Amgen Files BPCIA Complaint Against Celltrion Regarding Denosumab	10/06	AQ
AbbVie's tight grip on Humira market raises concerns about biosimilars	07/06	RE
AMGEN ANNOUNCES POSITIVE RESULTS FOR PHASE 3 REGISTRATIONAL TRIAL EVALUATING UPLIZNA FOR TREATMENT OF IMMUNOGLOBULIN G4-RELATED DISEASE	06/06	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Amgen Inc. Buenos Aires S.E.

Equities

AMGN

ARDEUT110665

Summary

Filters